Tumor Biology Rather Than Surgical Technique Dictates Prognosis in Colorectal Cancer Liver Metastases

Journal of Gastrointestinal Surgery

Volumn 20, Issue 11, 2016, Pages 1821-1829

  Margonis, Georgios Antonios ^a   Sasaki, Kazunari ^a   Kim, Yuhree ^a   Samaha, Mario ^a   Buettner, Stefan ^a   Amini, Neda ^a   Antoniou, Efstathios ^b   Pawlik, Timothy M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

CRLM; KRAS mutation; Tumor biology

Indexed keywords

KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; COLORECTAL TUMOR; FEMALE; GENETICS; HUMAN; LIVER RESECTION; LIVER TUMOR; MALE; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL ANALYSIS;

ADULT; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS P21(RAS); SURVIVAL ANALYSIS;

EID: 84978101512     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-016-3198-8     Document Type: Article

References (44)

1. Leung U, Gonen M, Allen PJ et al. Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. Ann Surg.2016.
2. Tzeng CW, Aloia TA. Colorectal liver metastases. J Gastrointest Surg.2013;17:195-201; quiz p 201-192.
3. Abbas S, Lam V, Hollands M. Ten-year survival after liver resection for colorectal metastases: systematic review and meta-analysis. ISRN Oncol.2011;2011:763245.
4. Pawlik TM, Schulick RD, Choti MA. Expanding criteria for resectability of colorectal liver metastases. Oncologist.2008;13:51-64.
5. Dhir M, Sasson AR. Surgical Management of Liver Metastases From Colorectal Cancer. J Oncol Pract.2016;12:33-39.
6. Cady B, Stone MD, McDermott WV, Jr. et al. Technical and biological factors in disease-free survival after hepatic resection for colorectal cancer metastases. Arch Surg.1992;127:561-568; discussion 568-569.
7. Ekberg H, Tranberg KG, Andersson R et al. Determinants of survival in liver resection for colorectal secondaries. Br J Surg.1986;73:727-731.
8. Are C, Gonen M, Zazzali K et al. The impact of margins on outcome after hepatic resection for colorectal metastasis. Ann Surg.2007;246:295-300.
9. Dhir M, Lyden ER, Wang A et al. Influence of margins on overall survival after hepatic resection for colorectal metastasis: a meta-analysis. Ann Surg.2011;254:234-242.
10. Hamady ZZ, Lodge JP, Welsh FK et al. One-millimeter cancer-free margin is curative for colorectal liver metastases: a propensity score case-match approach. Ann Surg.2014;259:543-548.
11. Kokudo N, Miki Y, Sugai S et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg.2002;137:833-840.
12. Mbah NA, Scoggins C, McMasters K et al. Impact of hepatectomy margin on survival following resection of colorectal metastasis: the role of adjuvant therapy and its effects. Eur J Surg Oncol.2013;39:1394-1399.
13. Truant S, Sequier C, Leteurtre E et al. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. HPB (Oxford).2015;17:176-184.
14. Eveno C, Karoui M, Gayat E et al. Liver resection for colorectal liver metastases with peri-operative chemotherapy: oncological results of R1 resections. HPB (Oxford).2013;15:359-364.
15. Pawlik TM, Scoggins CR, Zorzi D et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg.2005;241:715-722, discussion 722-714.
16. de Haas RJ, Wicherts DA, Flores E et al. R1 resection by necessity for colorectal liver metastases: is it still a contraindication to surgery? Ann Surg.2008;248:626-637.
17. Brudvik KW, Passot G, Vauthey JN. Colorectal Liver Metastases: A Changing Treatment Landscape. J Oncol Pract.2016;12:40-41.
18. Spolverato G, Ejaz A, Azad N et al. Surgery for colorectal liver metastases: The evolution of determining prognosis. World J Gastrointest Oncol.2013;5:207-221.
19. Brudvik KW, Kopetz SE, Li L et al. Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg.2015;102:1175-1183.
20. Margonis GA, Spolverato G, Kim Y et al. Effect of KRAS Mutation on Long-Term Outcomes of Patients Undergoing Hepatic Resection for Colorectal Liver Metastases. Ann Surg Oncol.2015;22:4158-4165.
21. Margonis GA, Kim Y, Spolverato G et al. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. JAMA Surg.2015;150:722-729.
22. Vauthey JN, Zimmitti G, Kopetz SE et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg.2013;258:619-626; discussion 626-617.
23. Schirripa M, Bergamo F, Cremolini C et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer.2015;112:1921-1928.
24. Sadot E, Groot Koerkamp B, Leal JN et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg.2015;262:476-485; discussion 483-475.
25. Andreou A, Aloia TA, Brouquet A et al. Margin status remains an important determinant of survival after surgical resection of colorectal liver metastases in the era of modern chemotherapy. Ann Surg.2013;257:1079-1088.
26. Angelsen JH, Horn A, Eide GE et al. Surgery for colorectal liver metastases: the impact of resection margins on recurrence and overall survival. World J Surg Oncol.2014;12:127.
27. Ayez N, Lalmahomed ZS, Eggermont AM et al. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol.2012;19:1618-1627.
28. Tranchart H, Chirica M, Faron M et al. Prognostic impact of positive surgical margins after resection of colorectal cancer liver metastases: reappraisal in the era of modern chemotherapy. World J Surg.2013;37:2647-2654.
29. Siriwardena AK, Mason JM, Mullamitha S et al. Management of colorectal cancer presenting with synchronous liver metastases. Nat Rev Clin Oncol.2014;11:446-459.
30. Bodingbauer M, Tamandl D, Schmid K et al. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg.2007;94:1133-1138.
31. Muratore A, Ribero D, Zimmitti G et al. Resection margin and recurrence-free survival after liver resection of colorectal metastases. Ann Surg Oncol.2010;17:1324-1329.
32. Welsh FK, Tekkis PP, O’Rourke T et al. Quantification of risk of a positive (R1) resection margin following hepatic resection for metastatic colorectal cancer: an aid to clinical decision-making. Surg Oncol.2008;17:3-13.
33. Yamamoto J, Shimada K, Kosuge T et al. Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg.1999;86:332-337.
34. Van Cutsem E, Nordlinger B, Adam R et al. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer.2006;42:2212-2221.
35. Brunner SM, Kesselring R, Rubner C et al. Prognosis according to histochemical analysis of liver metastases removed at liver resection. Br J Surg.2014;101:1681-1691.
36. Nielsen K, Rolff HC, Eefsen RL et al. The morphological growth patterns of colorectal liver metastases are prognostic for overall survival. Mod Pathol.2014;27:1641-1648.
37. Rekhtman N, Ang DC, Riely GJ et al. KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma. Mod Pathol.2013;26:1307-1319.
38. Santini D, Loupakis F, Vincenzi B et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist.2008;13:1270-1275.
39. Knijn N, Mekenkamp LJ, Klomp M et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer.2011;104:1020-1026.
40. Italiano A, Hostein I, Soubeyran I et al. KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: biological and clinical implications. Ann Surg Oncol.2010;17:1429-1434.
41. Etienne-Grimaldi MC, Formento JL, Francoual M et al. K-Ras mutations and treatment outcome in colorectal cancer patients receiving exclusive fluoropyrimidine therapy. Clin Cancer Res.2008;14:4830-4835.
42. Margonis GA, Spolverato G, Kim Y et al. Intraoperative surgical margin re-resection for colorectal liver metastasis: is it worth the effort? J Gastrointest Surg.2015;19:699-707.
43. Nuzzo G, Giuliante F, Ardito F et al. Influence of surgical margin on type of recurrence after liver resection for colorectal metastases: a single-center experience. Surgery.2008;143:384-393.
44. Cady B. Basic principles in surgical oncology. Arch Surg.1997;132:338-346.